• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • WORLD EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • WORLD EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Infographic: Why Isn’t There a Cure for Cancer?

    Bryan Mc Govern
    May. 22, 2017 03:30PM PST
    Pharmaceutical Investing
    Pharmaceutical Investing

    Medical research has reached new levels that make us question when will we be able to cure one of the most serious diseases.

    Cancer treatment continues to be a harrowing process for any patient, but medical improvements have been made to ease the treatment of this disease. However many often still ask when is a “cure” for cancer going to be found or made available to the masses.
    The key element to know about any cure is that cancer isn’t simple, as a disease it can take many forms and affect very different parts of the body, so not many cancers are the same and the way to treat them varies from the types and the affected area.
    Besides countless of large and small pharmaceutical companies working on a variety of treatments and different drugs to fight cancer, efforts in the US include a funded massive moonshot program that has put the goal to get cancer under a manageable situation, the program was created by former Vice President Joe Biden following the death of his son Beau Biden to brain cancer.


    This year the government of Canada announced a partnership between The National Research Council of Canada and the Toronto-based Centre for the Commercialization of Antibodies and Biologics in order to accelerate cancer research and hopefully medical advancements.
    “The goal of the collaboration is to identify the most promising antibodies, and increase their value by generating data that effectively de-risks each asset. CCAB’s objective is to then license lead antibody candidates to seed newly formed Canadian biotechnology companies,” said the press release.
    The American Society of Clinical Oncology released a report on the most significant clinical growth combating the disease in 2016.
    “Much work still lies ahead. Many questions remain about how cancer develops and spreads and how best to treat it… I hope you are as inspired as I am by the gains the clinical cancer research community has made over the past year and by the promise of a new era of advances just over the horizon,” said Dr. Daniel Hayes in the report.
    That said, the Investing News Network took a look at the possibilities of significant improvements to cancer treatment under the Donald Trump presidency.
    The below infographic from HealthGrad.com  details why there isn’t a direct cure for cancer.

    Don’t forget to follow us @INN_LifeScience for real-time news updates!
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    pharmaceutical investingbiotechnology companiescanadacancer treatmentcancer cellscancer research
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×